葡萄糖胺3-O-硫酸盐 | 76330-20-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 葡萄糖胺3-O-硫酸盐
• 英文名称: [(2R,3R,4R,5R)-2-amino-4,5,6-trihydroxy-1-oxohexan-3-yl] hydrogen sulfate
• CAS: 76330-20-6
• 化学式: C₆H₁₃NO₈S
• 分子量: 259.24
• InChiKey: GXYKBDAKQXPXFV-SLPGGIOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.4
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  176
• 氢给体数：
  5
• 氢受体数：
  9

安全信息

• WGK Germany：
  3

文献信息

• [EN] LINKAGE MODIFIED OLIGOMERIC COMPOUNDS<br/>[FR] COMPOSÉS OLIGOMÈRES MODIFIÉS PAR LIAISON
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2015168172A1

  公开（公告）日：2015-11-05

  The present invention provides oligomeric compounds comprising at least one neutral methoxypropyl phosphonate modified internucleoside linkage. Such oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Such oligomeric compounds have enhanced stability to exposure to base during synthesis. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.

  本发明提供了含有至少一种中性甲氧基丙基磷酸酯修饰的核苷间连接的寡聚化合物。这种寡聚化合物具有一个或多个改进的性质，如选择性、效力、改进的毒性谱和/或改进的促炎谱。这种寡聚化合物在合成过程中对碱的暴露具有增强的稳定性。某些这种寡聚化合物对于与细胞中的互补核酸杂交是有用的，包括但不限于核酸。在某些实施例中，杂交导致调节细胞中目标核酸的活性或表达量。
• Immunomodulating compositions for treatment of immune system disorders
  申请人：——

  公开号：US20010009680A1

  公开（公告）日：2001-07-26

  The present invention relates to a composition for use as an immunomodulator comprising small molecular weight components of less than 3000 daltons, and having the following properties: a) is extractable from bile of animals; b) is capable of stimulating monocytes and macrophages in vitro and in vivo; c) is capable of modulating tumor necrosis factor production; d) contains no measurable IL-1&agr;, IL-1&bgr;, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-&ggr;; e) has an anti-proliferative effect in a malignant mouse hybridoma cell line; f) shows no cytotoxicity to human peripheral blood mononuclear cells or lymphocytes; and g) is not an endotoxin. The invention also relates to a method of preparing the composition, its use as an immunomodulator, and its use in the treatment of diseases and conditions having an immunological component.

  本发明涉及一种用作免疫调节剂的组合物，包括小分子量成分，分子量小于3000道尔顿，并具有以下特性：a）可从动物的胆汁中提取；b）能够在体外和体内刺激单核细胞和巨噬细胞；c）能够调节肿瘤坏死因子的产生；d）不含可测量的IL-1α、IL-1β、TNF、IL-6、IL-8、IL-4、GM-CSF或IFN-γ；e）对恶性小鼠杂交瘤细胞系具有抗增殖作用；f）对人类外周血单核细胞或淋巴细胞没有细胞毒性；g）不是内毒素。该发明还涉及一种制备该组合物的方法，其用作免疫调节剂，并在治疗具有免疫成分的疾病和病况中的应用。
• [EN] FLUORESCENT PERYLENE DERIVATIVES FOR DIRECT DETECTION OF HEPARIN<br/>[FR] DÉRIVÉS DE PÉRYLÈNE FLUORESCENTS POUR LA DÉTECTION DIRECTE DE L'HÉPARINE
  申请人：UNIV RUPRECHT KARLS HEIDELBERG

  公开号：WO2011020887A1

  公开（公告）日：2011-02-24

  The invention relates to a perylene diimide derivative and to an in vitro method for preparing the same. In addition, the invention relates to a method for detecting heparin in a sample using perylene diimide derivatives, wherein the interaction of the perylene diimide derivative with heparin modulates the intensity of the fluorescent signal of the mixture compared to the solution. The invention also comprises a diagnostic kit for detecting heparin in a sample in vitro, comprising the perylene diimide derivative, as well as the use of the perylene diimide derivative for neutralizing the anticoagulant activity of heparin.

  该发明涉及一种苝二酰亚胺衍生物以及一种用于体外制备该衍生物的方法。此外，该发明涉及一种使用苝二酰亚胺衍生物检测样品中肝素的方法，其中苝二酰亚胺衍生物与肝素的相互作用调节了混合物的荧光信号强度，相较于溶液。该发明还包括一种体外检测样品中肝素的诊断试剂盒，包括苝二酰亚胺衍生物，以及使用苝二酰亚胺衍生物中和肝素抗凝活性的方法。
• [EN] SULFATED OLIGOSACCHARIDES FOR USE IN TREATMENT OF NEURODEGENERATIVE DISEASES<br/>[FR] OLIGOSACCHARIDES SULFATÉS À UTILISER DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
  申请人：KING S COLLEGE LONDON

  公开号：WO2012160337A1

  公开（公告）日：2012-11-29

  Compounds which interact with HlsTONES Compounds of Formula I : • 4"'-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4'-Sulfo-Fu- cose [alpha]1-4-Glucuronic acid [beta]1-0-Methyl or • 4" "-Sulfo-Fucose [alpha]1-3 (4"-sulfo)-Fucose [alpha]1-3 (4"-sulfo)- Fucose [alpha]1-3 (4'-Sulfo-Fucose [alpha]1-4-Glucuronic acid [be ta]1-0-Methyl. wherein X is sulfate (-SO3H) or phosphate (-PO3H); Su is sulfate and sulfation is most likely at the arrowed positions. The compounds above are useful in the inhibition of histones, in particular histone H1. The compounds can be used in medicine and particularly in the prevention and/or treatment of a wide variety of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

  与HlsTONES Formula I 化合物相互作用的化合物包括：• 4"'-糖基硫酸酯 [alpha]1-3 (4"-糖基硫酸酯) [alpha]1-3 (4'-糖基硫酸酯 [alpha]1-4-葡萄糖醛酸 [beta]1-0-甲基或• 4" "-糖基硫酸酯 [alpha]1-3 (4"-糖基硫酸酯) [alpha]1-3 (4"-糖基硫酸酯)- 糖基 [alpha]1-3 (4'-糖基硫酸酯 [alpha]1-4-葡萄糖醛酸 [be ta]1-0-甲基。其中 X 是硫酸酯基 (-SO3H) 或磷酸酯基 (-PO3H)；Su 是硫酸酯基，磺酸化最有可能发生在箭头所指位置。上述化合物对于抑制组蛋白，特别是组蛋白 H1，具有用处。这些化合物可用于医药领域，尤其是用于预防和/或治疗多种神经退行性疾病，包括阿尔茨海默病和帕金森病。
• Method for the treatment and prevention of pain and inflammation with glucosamine and a cyclooxygenase-2 selective inhibitor and compositions therefor
  申请人：Pharmacia Corporation

  公开号：US20030114418A1

  公开（公告）日：2003-06-19

  A method of treating, preventing, or inhibiting pain, inflammation or inflammation-associated disorder in a subject in need of such treatment or prevention provides for treating the subject with glucosamine and a cyclooxygenase-2 selective inhibitor or prodrug thereof, wherein the amount of glucosamine and the amount of a cyclooxygenase-2 selective inhibitor or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount of the composition. Compositions and pharmaceutical compositions that contain glucosamine and a cyclooxygenase-2 selective inhibitor are also disclosed.

  一种治疗、预防或抑制需要此类治疗或预防的受试者的疼痛、炎症或与炎症相关疾病的方法包括使用氨基葡萄糖和环氧合酶-2选择性抑制剂或其前药来治疗受试者，其中氨基葡萄糖的量和环氧合酶-2选择性抑制剂或其前药的量共同构成组合物的疼痛或炎症抑制治疗或预防的有效量。还公开了含有氨基葡萄糖和环氧合酶-2选择性抑制剂的组合物和药物组合物。